Abstract: The invention relates to the combination of: a short-acting hypnotic agent which is selected from among a modulators of receptors GABA-A, a benzodiazepine, a phenothiazine, a melatonin derivative and a melatonin receptor agonist; and a long-acting hypnotic agent which is selected from among a modulator of receptors GABA-A, a benzodiazepine, an antagonist of receptors 5HT2A and a calcium ion modulator, for the treatment of sleep disorders. The invention also relates to galenic formulations containing said combinations.

Abstract: The invention relates to the combination of: a short-acting hypnotic agent which is selected from among a modulators of receptors GABA-A, a benzodiazepine, a phenothiazine, a melatonin derivative and a melatonin receptor agonist; and a long-acting hypnotic agent which is selected from among a modulator of receptors GABA-A, a benzodiazepine, an antagonist of receptors 5HT2A and a calcium ion modulator, for the treatment of sleep disorders. The invention also relates to galenic formulations containing said combinations.

Abstract: The invention concerns a sprayer (12) actuating device comprising a support (22) whereon the sprayer (12) is supported and a member (24) actuating the sprayer knob (18) mobile axially relative to the support by action of the control means (34, 36, 43, 46, 47, 58) between a position driving in the knob (18) and a position releasing it, the control means (34, 36, 43, 47, 58) comprising elastic means (36) for urging the actuating member in depressing position and means capable of disengaging (58) the lock of the actuating member into releasing position. The control means comprise a rotatable handle (43) manually actuated by a user and associated to a cam (43) moving the actuating member (24) from the depressing position to the releasing position.

Abstract: The invention concerns a pharmaceutical composition for transdermal administration, characterized in that it comprises:a) optionally, a polymeric release matrix capable of forming a flexible film after drying, chosen from cellulose polymers or copolymers or vinylpyrrolidone/vinyl acetate copolymersb) an active principlec) a promoter of transcutaneous absorption of the active principled) a physiologically acceptable non-aqueous solvent capable of dissolving the release matrix, the active principle and the transcutaneous absorption promoter and also capable of being rapidly removed by evaporation on contact with the skin.

Abstract: A device comprising a reversible negative electrode in contact with a reservoir element containing an electrolyte which contains an active principle such as an anionic oligosaccharide, particularly a pentasaccharide, in at least partially ionised form, a positive electrode alone or in combination with an electrolyte-containing receptacle, and an electrical signal generator connectable to both electrodes. The generator is arranged to apply electrical signals between the electrodes, which signals have an average voltage such that the average current density generated between the electrodes is 0.05-0.25 mA/cm.sup.2. The amount of active principle in the reservoir element combined with the negative electrode is 0.5-12 mg per cm.sup.2. The amount of active principle in the reservoir element combined with the negative electrode is 0.5-12 mg per cm.sup.2 and per mAh of current through 1 cm.sup.2 of the electrode.

Abstract: An iontophoresis device in which at least one of the electrodes is a composite electrode containing a polymeric binder, a powdered or fibrous conductive filler and a divided material capable of being consumed by electrochemical oxidation or reduction. The binder of the composite electrode consists of a polymer containing 10-100 mo % of 1,2-epoxypropane and/or 1,2-epoxybutane, and 40-0 mol % of at least one other monomer that is copolymerizable with such oxides. The device is useful for transcutaneously delivering active principles to a patient.